Menu Search Donate
Drug dosage identifier

Spironolactone

This document is only valid for the day on which it is accessed. Please read our disclaimer.

Dose and administration

1-3 mg/kg/dose daily PO.

Indications

  1. Used in combination with other diuretics in the treatment of congestive heart failure and BPD (situations of increased aldosterone secretion).

Contraindications and precautions

  1. Known hypersensitivity to spironolactone
  2. Significant impairment of renal function, especially anuria
  3. Caution in neonates with severe liver dysfunction
  4. Hyperkalaemia
  5. Caution in neonates receiving potassium supplements
  6. Should not be used concurrently with other potassium sparing agents.

Clinical pharmacology

Spironolactone is a specific pharmacological antagonist of aldosterone. Acts primarily through competitive binding of receptors at the aldosterone dependent sodium-potassium exchange site in the distal convoluted renal tubule. Causes increased urinary excretion of sodium and water while potassium is retained. Also has an effect on tubular transported calcium, resulting in increased urinary calcium excretion. Spironolactone has moderate anti-androgenic activity in humans.

Well absorbed from the gastrointestinal tract (bioavailability >90%). Very high protein binding (98%) to human plasma protein. Rapidly and completely metabolised to a large number of metabolites. The major active metabolite is canrenone which has a slow clearance. The activity of canrenone is 10-33 % that of spironolactone. Elimination of canrenone and other metabolites is primarily in the urine (50%) but they also appear in bile (5-33%).

The onset of action of spironolactone is usually observed 2-3 days after commencement of therapy. The effects of aldosterone involve the synthesis of protein or peptide subsequent to its combination with its receptor. The activity of the protein or peptide persist for 2-3 days. With long-term use of spironolactone the elimination half-life is 13-24 hours. The duration of effect persists for 2-3 days following discontinuation of therapy.

Possible adverse effects

  1. Gastrointestinal disturbances (nausea, vomiting, diarrhoea).
  2. Lethargy, irritability.
  3. Paraesthesia, weakness, flaccid paralysis and tetany.
  4. Rashes
  5. Dose dependent androgenic effects (females), gynaecomastia (males).

Special considerations

  1. Monitor urea and electrolytes frequently. Anticipate hyperkalaemia, hypocalaemia, hyponatraemia, transient elevation of urea.
  2. Reversible hyperchloraemic metabolic acidosis, usually in association with hyperkalaemia, has been reported in patients with severe liver dysfunction, even in the presence of normal renal function.
  3. Spironolactone has been shown to increase the elimination half-life of digoxin. May result in increased serum digoxin levels and subsequent digoxin toxicity.
  4. Several reports of possible interference with digoxin radioimmunoassays by spironolactone, or its metabolites, have appeared in the literature. Neither the extent nor the potential clinical significance of its interference has been fully established.

Management of Spironolactone administration

Description

Pale yellow suspension 5 mg/ml dispensed by the Pharmacy.

Prescription

Charted on prescription chart in mg/dose.

Administration

  1. Shake well before use as the ingredients will settle at the bottom of the bottle on standing.
  2. Can be administered independant of food.

Observation and documentation

  1. Assess for signs of adverse effects
  2. Monitor fluid balance
  3. Monitor BP at regular intervals

Storage

  • Refrigerate - do NOT freeze
  • Protect from light
  • Expiry as on bottle

Selected references

  1. Roberts RJ. In: Drug therapy in infants: Pharmacologic principles and clinical experience. Philadelphia, WB Saunders 1984, p243-4. 
  2. Karim A. Spironolactone; disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev 1978; 8:151. 
  3. Overdiek HWPM, Hermens WAJJ, Merkus FWHM. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 1985; 38:469.

Did you find this information helpful?

Document Control

  • Date last published: 30 March 1996
  • Document type: Drug Dosage Guideline
  • Services responsible: ADHB Pharmacy, Neonatology
  • Editor: Sarah Bellhouse
  • Review frequency: 2 years